WHITEPAPER: When biotech and pharma companies transport investigational medical products (IMPs) internationally, they are often required to pay import
WHITEPAPER: A clinical distribution plan must be solid enough to begin planning activities, and flexible enough to adapt to inevitable changes. A good
WHITEPAPER: China’s sizeable population makes it an alluring market for pharmaceutical markets. There are many aspects that make it an attractive location to run clinical trials, as well as some challenges that we will explore in this article
WHITEPAPER: By its nature, EU compassionate use supply is needed urgently. This means packaging, labeling, and distribution must be executed rapidly and efficiently
WHITEPAPER: Importing clinical supplies into Japan requires a level of precision not seen anywhere else in the world. Download the whitepaper here.
WHITEPAPER: Tris Evans, Gavin Morgan, Uday Pathapati discuss what factors need to be considered from a quality, packaging and labeling, logistical and risk management perspective when planning an EU Compassionate Use Program...
When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?
Start your PCI experience today.Your bridge between life-changing therapies and patients.
